MOTS-c — Wolverine Health

How it works

Encoded in mitochondrial DNA — not nuclear DNA. That's unusual. It's the first peptide shown to have a mitochondrial genetic origin with systemic metabolic effects. Mouse models show it shifts metabolism toward fat burning and makes cells respond better to insulin — effects that look a lot like what exercise does. Human circulating levels decline with age and metabolic disease. The exercise-mimetic angle is what drives interest. The human evidence base is observational — what we know is that the levels change; what we don't know is whether supplementing them does what it does in mice.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration (obesity and osteoporosis indications).
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

A mitochondrial derived peptide MOTS-c promotes metabolic homeostasis — Lee et al. (2015), Cell Metabolism

MOTS-c, encoded within the mitochondrial 12S rRNA, promotes metabolic homeostasis by regulating glucose uptake and fatty acid metabolism, with circulating levels declining with age in both mice and humans.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on MOTS-c

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

MOTs-C vs Epitalon: two longevity peptides, two evidence standards

WADA

MOTs-C and Epitalon both get sold as longevity peptides. They face the FDA's PCAC review on consecutive days in July for completely different indications. Here is what their two very different evidence standards actually look like.

Mitochondrial-derived peptides: the signalling class behind MOTs-c

Mitochondrial-derived peptides are short signals encoded inside the mitochondrial genome — a class your textbooks didn't have ten years ago. Here is what they are, what the animal mechanism work shows, and where MOTs-c sits in the July 2026 FDA review.

MOTS-c: the mitochondrial peptide rewriting the longevity playbook

MOTS-c is sold as exercise in a vial — a peptide that works the same pathways your body uses to get fit and stay young. Here is what the research actually shows, what the human evidence looks like, and where the July 2026 FDA review fits.

MOTS-c: Mitochondrial Peptide Research in Metabolism and Longevity

Science-journalism overview of MOTS-c — the mitochondrial-derived peptide studied for metabolic regulation and exercise mimicry, what the preclinical and early human data show, and its position on the PCAC July 23–24 2026 docket.